|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 22, 2017 )
Urinary incontinence is a loss of control of the bladder. In some cases it may result in a total loss of the bladder's contents or it may just cause minor leakage. Symptoms include stress incontinence rashes and other skin disorders. Risk factors include age gender overweight smoking and other kidney diseases. Treatment includes anticholinergics and topical estrogen.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Urinary Incontinence-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Urinary incontinence (Genito Urinary System And Sex Hormones) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.
The Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Pre-Registration Phase III Phase II Phase I Preclinical and Discovery stages are 1 3 6 1 4 and 1 respectively. Similarly the Universities portfolio in Phase II stages comprises 1 molecules respectively.
Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/urinary-incontinence-pipeline-review-h2-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Urinary Incontinence (Genito Urinary System And Sex Hormones) .
- The pipeline guide reviews pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001881432/sample
Reasons to buy
- Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Astellas Pharma Inc
Beech Tree Labs Inc
Celogos SA
Crystec Ltd
FemmePharma Global Healthcare Inc
GTx Inc
Innovacell Biotechnologie AG
Ipsen SA
Pfizer Inc
Taiho Pharmaceutical Co Ltd
Takeda Pharmaceutical Company Ltd
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001881432/discount
List of Tables
Number of Products under Development for Urinary Incontinence H2 2017
Number of Products under Development by Companies H2 2017
Number of Products under Development by Universities/Institutes H2 2017
Products under Development by Companies H2 2017
Products under Development by Universities/Institutes H2 2017
Number of Products by Stage and Target H2 2017
Number of Products by Stage and Mechanism of Action H2 2017
Number of Products by Stage and Route of Administration H2 2017
Number of Products by Stage and Molecule Type H2 2017
Urinary Incontinence-Pipeline by Astellas Pharma Inc H2 2017
Urinary Incontinence-Pipeline by Beech Tree Labs Inc H2 2017
Urinary Incontinence-Pipeline by Celogos SA H2 2017
Urinary Incontinence-Pipeline by Crystec Ltd H2 2017
Urinary Incontinence-Pipeline by FemmePharma Global Healthcare Inc H2 2017
Urinary Incontinence-Pipeline by GTx Inc H2 2017
Urinary Incontinence-Pipeline by Innovacell Biotechnologie AG H2 2017
Urinary Incontinence-Pipeline by Ipsen SA H2 2017
Urinary Incontinence-Pipeline by Pfizer Inc H2 2017
Urinary Incontinence-Pipeline by Taiho Pharmaceutical Co Ltd H2 2017
Urinary Incontinence-Pipeline by Takeda Pharmaceutical Company Ltd H2 2017
Urinary Incontinence-Dormant Projects H2 2017
Urinary Incontinence-Dormant Projects H2 2017 (Contd..1) H2 2017
Urinary Incontinence-Discontinued Products H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001881432/buy/2000
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
